Balance Sheet
Accounts PayablesAccumulated ExpensesCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Current Deferred Revenue: 2023-2024

  • Zhengye Biotechnology Holding's Current Deferred Revenue fell 25.35% to $477,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $477,000, marking a year-over-year decrease of 25.35%. This contributed to the annual value of $477,000 for FY2024, which is 26.73% down from last year.
  • As of Q4 2024, Zhengye Biotechnology Holding's Current Deferred Revenue stood at $477,000, which was down 25.35% from $639,021 recorded in Q4 2023.
  • Zhengye Biotechnology Holding's Current Deferred Revenue's 5-year high stood at $639,021 during Q4 2023, with a 5-year trough of $477,000 in Q4 2024.
  • For the 2-year period, Zhengye Biotechnology Holding's Current Deferred Revenue averaged around $558,010, with its median value being $558,010 (2023).
  • Data for Zhengye Biotechnology Holding's Current Deferred Revenue shows a maximum YoY fell of 25.35% (in 2024) over the last 5 years.
  • Zhengye Biotechnology Holding's Current Deferred Revenue (Quarterly) stood at $639,021 in 2023, then fell by 25.35% to $477,000 in 2024.